Catherine S Forster1,2, Michael H Hsieh2,3, Marcos Pérez-Losada4,5, Ljubica Caldovic6, Hans Pohl3, Inger Ljungberg7, Bruce Sprague3, Crystal Stroud6, Suzanne Groah7. 1. Department of Pediatrics, Children's National Health Systems, Washington, DC, USA. 2. Biomedical Research Institute, Rockville, Maryland, USA. 3. Department of Urology, Children's National Health Systems, Washington, DC, USA. 4. Computational Biology Institute, Milken Institute School of Public Health, George Washington University, Ashburn, Virginia, USA. 5. CIBIO-InBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Campus Agrário de Vairão, Vairão, Portugal. 6. Children's Research Institute, Children's National Health Systems, Washington, DC, USA. 7. Paralysis Rehabilitation and Recovery Program, Spinal Cord Injury Research, MedStar National Rehabilitation Hospital, Washington, DC, USA.
Abstract
Context/objective: Manipulation of the microbiome is an emerging approach to promote health. We conducted a Phase Ia safety study of a single bladder instillation of probiotics in asymptomatic patients with neuropathic bladder to determine the tolerability and safety of a single Lactobacillus instillation.Design: Phase Ia safety study.Setting: Outpatient rehabilitation clinic at a rehabilitation hospital (adults) and urology clinic at a free-standing children's hospital (children).Participants: Ten patients with neuropathic bladder were included: five children with spina bifida and five adults with spinal cord injury.Interventions: A single Lactobacillus rhamnosus GG (Culturelle, 20 billion live organisms) instillation.Outcome measures: After the instillation, participants self-monitored symptoms using the Urinary Symptoms Questionnaire for People with Neuropathic Bladder using Intermittent Catheterization daily for one week. Repeat urinalysis, urine culture, and 16S bacterial rRNA-based microbiome analyses were performed 7-10 days after instillation. Results: Probiotic instillation was well-tolerated. One child had upper respiratory tract symptoms during the trial, and two had transient cloudy urine. No adults reported any symptoms following instillation. Lactobacillus did not grow on culture post-instillation. There were differences in beta diversity of the urine microbiome in children vs. adults with neuropathic bladder (P < 0.0156). Lactobacillus was present in the pre-instillation urinary microbiomes all of the adults and 4 out of 5 of the pediatric subjects, and identified in 4 out of 5 of both the adult and pediatric subjects' post-instillation urinary microbiomes. Conclusion: Intravesical instillation of Culturelle probiotic may be safe and well-tolerated in patients with neuropathic bladder.
Context/objective: Manipulation of the microbiome is an emerging approach to promote health. We conducted a Phase Ia safety study of a single bladder instillation of probiotics in asymptomatic patients with neuropathic bladder to determine the tolerability and safety of a single Lactobacillus instillation.Design: Phase Ia safety study.Setting: Outpatient rehabilitation clinic at a rehabilitation hospital (adults) and urology clinic at a free-standing children's hospital (children).Participants: Ten patients with neuropathic bladder were included: five children with spina bifida and five adults with spinal cord injury.Interventions: A single Lactobacillus rhamnosus GG (Culturelle, 20 billion live organisms) instillation.Outcome measures: After the instillation, participants self-monitored symptoms using the Urinary Symptoms Questionnaire for People with Neuropathic Bladder using Intermittent Catheterization daily for one week. Repeat urinalysis, urine culture, and 16S bacterial rRNA-based microbiome analyses were performed 7-10 days after instillation. Results: Probiotic instillation was well-tolerated. One child had upper respiratory tract symptoms during the trial, and two had transient cloudy urine. No adults reported any symptoms following instillation. Lactobacillus did not grow on culture post-instillation. There were differences in beta diversity of the urine microbiome in children vs. adults with neuropathic bladder (P < 0.0156). Lactobacillus was present in the pre-instillation urinary microbiomes all of the adults and 4 out of 5 of the pediatric subjects, and identified in 4 out of 5 of both the adult and pediatric subjects' post-instillation urinary microbiomes. Conclusion: Intravesical instillation of Culturelle probiotic may be safe and well-tolerated in patients with neuropathic bladder.
Authors: Patrick D Schloss; Sarah L Westcott; Thomas Ryabin; Justine R Hall; Martin Hartmann; Emily B Hollister; Ryan A Lesniewski; Brian B Oakley; Donovan H Parks; Courtney J Robinson; Jason W Sahl; Blaz Stres; Gerhard G Thallinger; David J Van Horn; Carolyn F Weber Journal: Appl Environ Microbiol Date: 2009-10-02 Impact factor: 4.792
Authors: Thomas M Hooton; Suzanne F Bradley; Diana D Cardenas; Richard Colgan; Suzanne E Geerlings; James C Rice; Sanjay Saint; Anthony J Schaeffer; Paul A Tambayh; Peter Tenke; Lindsay E Nicolle Journal: Clin Infect Dis Date: 2010-03-01 Impact factor: 9.079
Authors: Suzanne L Groah; Marcos Pérez-Losada; Ljubica Caldovic; Inger H Ljungberg; Bruce M Sprague; Eduardo Castro-Nallar; Neel J Chandel; Michael H Hsieh; Hans G Pohl Journal: J Urol Date: 2016-01-22 Impact factor: 7.450
Authors: Derrick E Fouts; Rembert Pieper; Sebastian Szpakowski; Hans Pohl; Susan Knoblach; Moo-Jin Suh; Shih-Ting Huang; Inger Ljungberg; Bruce M Sprague; Sarah K Lucas; Manolito Torralba; Karen E Nelson; Suzanne L Groah Journal: J Transl Med Date: 2012-08-28 Impact factor: 5.531
Authors: Stefania Musco; Alessandro Giammò; Francesco Savoca; Luca Gemma; Paolo Geretto; Marco Soligo; Emilio Sacco; Giulio Del Popolo; Vincenzo Li Marzi Journal: J Clin Med Date: 2022-06-14 Impact factor: 4.964
Authors: Virginia Perez-Carrasco; Ana Soriano-Lerma; Miguel Soriano; José Gutiérrez-Fernández; Jose A Garcia-Salcedo Journal: Front Cell Infect Microbiol Date: 2021-05-18 Impact factor: 5.293
Authors: Suzanne L Groah; Amanda K Rounds; Inger H Ljungberg; Bruce M Sprague; Jamie K Frost; Rochelle E Tractenberg Journal: Ther Adv Urol Date: 2019-10-03